J. Versluis

发表

Learning from clinical trials of neoadjuvant checkpoint blockade

C. Blank, G. Long, J. Versluis, 2020, Nature Medicine.

Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors

C. Blank, G. Long, P. Dimitriadis, 2022, Science Translational Medicine.

Diagnostic performance of early increase in S100B or LDH as outcome predictor for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.

E. Rozeman, C. Blank, S. Wilgenhof, 2022, Clinica chimica acta; international journal of clinical chemistry.

The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

P. Ascierto, E. D. de Vries, Douglas B. Johnson, 2021, European journal of cancer.

Non-islet cell tumour hypoglycaemia in a patient with a well-differentiated gastric neuroendocrine tumour

G. Valk, M. Tesselaar, H. V. van Rossum, 2019, BMJ Case Reports.

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach

C. Blank, D. Thommen, J. Versluis, 2020, Journal for ImmunoTherapy of Cancer.

LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study

R. Scolyer, S. Cornelissen, G. Long, 2021, Annals of Oncology.

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

K. Shannon, R. Scolyer, K. Sikorska, 2022, Nature Medicine.

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

N. Ajami, K. Shannon, J. Wargo, 2022, Nature Medicine.

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

A. Gesierich, K. Kähler, S. Ugurel, 2022, European journal of cancer.

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.

L. Pickering, Douglas B. Johnson, C. Blank, 2022, European journal of cancer.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

M. Weichenthal, K. Kähler, P. Ascierto, 2022, Journal for ImmunoTherapy of Cancer.

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

K. Sikorska, J. Haanen, H. Eriksson, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

M. Weichenthal, J. Utikal, D. Schadendorf, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

A. Hauschild, D. Schadendorf, R. Sullivan, 2020, British Journal of Cancer.

First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.

K. Sikorska, E. Rozeman, C. Blank, 2020 .

Learning from clinical trials of neoadjuvant checkpoint blockade

C. Blank, G. Long, J. Versluis, 2020, Nature Medicine.

Spatial proximity of CD8 T cells to tumor cells as an independent biomarker for response to anti-PD-1 therapy.

H. Horlings, A. Broeks, T. Schumacher, 2020 .

Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis

A. Gesierich, K. Kähler, S. Ugurel, 2022, Data in brief.

Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma

E. Rozeman, C. Blank, J. Versluis, 2023, Nature Reviews Clinical Oncology.

IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma

A. Broeks, R. Scolyer, D. Peeper, 2023, The Journal of experimental medicine.

Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.

Douglas B. Johnson, C. Blank, G. Long, 2021 .

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation

A. Broeks, K. Sikorska, E. Rozeman, 2022, Journal for ImmunoTherapy of Cancer.

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma.

B. Schilling, R. Scolyer, E. Rozeman, 2021, European journal of cancer.

3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)

T. Schumacher, K. Sikorska, C. Blank, 2019, Annals of Oncology.

Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.

A. Broeks, R. Scolyer, O. Krijgsman, 2020 .

Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials

A. Broeks, T. Schumacher, R. Scolyer, 2020 .

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

T. Harrer, L. Heinzerling, C. Blank, 2023, Cancer Immunology, Immunotherapy.

Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma

P. Dimitriadis, E. Hoefsmit, J. Versluis, 2024, Cancer immunology, immunotherapy : CII.

Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence

D. Schadendorf, R. Dummer, E. Rozeman, 2023, Cancer research communications.

Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma

J. Wilmott, W. V. van Houdt, P. Dimitriadis, 2024, Journal for ImmunoTherapy of Cancer.

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

K. Shannon, A. Broeks, T. Schumacher, 2021, Nature Medicine.